Patents by Inventor Matthew Alexander James Duncton
Matthew Alexander James Duncton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240116870Abstract: Described herein are compounds that are derivatives of DMT or 5-MeO-DMT and can be metabolically converted to N,N-dimethyltryptamine or analogs thereof upon administration to a subject. In certain embodiments, the compounds described herein are useful for the treatment of conditions associated with a neurological disease.Type: ApplicationFiled: October 10, 2023Publication date: April 11, 2024Inventors: Matthew Alexander James DUNCTON, Sam CLARK
-
Patent number: 11866408Abstract: Described herein are compounds that are derivatives of DMT or 5-MeO-DMT and can be metabolically converted to N,N-dimethyltryptamine or analogs thereof upon administration to a subject. In certain embodiments, the compounds described herein are useful for the treatment of conditions associated with a neurological disease.Type: GrantFiled: February 23, 2023Date of Patent: January 9, 2024Assignee: TERRAN BIOSCIENCES INC.Inventors: Matthew Alexander James Duncton, Sam Clark
-
Publication number: 20230212119Abstract: Described herein are compounds that are derivatives of DMT or 5-MeO-DMT and can be metabolically converted to N,N-dimethyltryptamine or analogs thereof upon administration to a subject. In certain embodiments, the compounds described herein are useful for the treatment of conditions associated with a neurological disease.Type: ApplicationFiled: February 23, 2023Publication date: July 6, 2023Inventors: Matthew Alexander James DUNCTON, Sam CLARK
-
Publication number: 20230201218Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: February 28, 2023Publication date: June 29, 2023Applicant: Arixa Pharmaceuticals, Inc.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20200297733Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: June 8, 2020Publication date: September 24, 2020Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
-
Patent number: 10722521Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: October 16, 2019Date of Patent: July 28, 2020Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20200046724Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the f-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: October 16, 2019Publication date: February 13, 2020Applicant: ARIXA PHARMACEUTICALS, INC.Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
-
Patent number: 10500211Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: August 29, 2018Date of Patent: December 10, 2019Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20190022102Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: ApplicationFiled: August 29, 2018Publication date: January 24, 2019Inventors: ERIC M. GORDON, JOHN FREUND, MARK A. GALLOP, MATTHEW ALEXANDER JAMES DUNCTON
-
Patent number: 10085999Abstract: ?-Lactamase inhibiting compounds, therapeutic methods of using the ?-lactamase inhibiting compounds, particularly in combination with ?-lactam antibiotics and pharmaceutical compositions thereof are disclosed. The ?-lactamase inhibiting compounds are suitable for oral administration.Type: GrantFiled: March 23, 2018Date of Patent: October 2, 2018Assignee: ARIXA PHARMACEUTICALS, INC.Inventors: Eric M. Gordon, John Freund, Mark A. Gallop, Matthew Alexander James Duncton
-
Publication number: 20120088746Abstract: Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.Type: ApplicationFiled: May 10, 2007Publication date: April 12, 2012Applicants: PFIZER INC., RENOVIS, INC.Inventors: Yuji Shishido, Kazunari Nakao, Satoshi Nagayama, Hirotaka Tanaka, Matthew Alexander James Duncton, Matthew Cox, John Kincaid, Kiran Sahasrabudhe, Maria de Los Angeles Estiarte-Martinez
-
Patent number: 8153651Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.Type: GrantFiled: November 13, 2008Date of Patent: April 10, 2012Assignee: Evotec AGInventors: Matthew Cox, Donogh John Roger O'Mahony, Maria De Los Angeles Estiarte-Martinez, Tadashi Kawashima, Satoshi Nagayama, Yuji Shishido, Hirotaka Tanaka, Matthew Alexander James Duncton, Andrew Antony Calabrese
-
Patent number: 7964732Abstract: This invention provides a compound of the formula These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.Type: GrantFiled: November 9, 2007Date of Patent: June 21, 2011Assignee: Pfizer Inc.Inventors: Koji Ando, Andrew Anthony Calabrese, Matthew Alexander James Duncton, Kentaro Futatsugi, Misato Hirano, Satochi Nagayama
-
Publication number: 20110021514Abstract: Compounds are disclosed that have a formula represented by the following: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.Type: ApplicationFiled: November 13, 2008Publication date: January 27, 2011Applicants: RENOVIS, INC., PFIZER GLOBAL RESEARCH AND DEVELOPMENTInventors: Matthew Cox, Donogh John Roger O'Mahony, Maria De Los Angeles Estiarte-Martinez, Tadashi Kawashima, Satoshi Nagayama, Yuji Shishido, Hirotaka Tanaka, Matthew Alexander James Duncton, Andrew Antony Calabrese
-
Publication number: 20100267769Abstract: This invention provides a compound of the formula These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.Type: ApplicationFiled: November 9, 2007Publication date: October 21, 2010Inventors: Koji Ando, Andrew Anthony Calabrese, Matthew Alexander James Duncton, Kentaro Futatsugi, Misato Hirano, Satochi Nagayama
-
Patent number: 7145009Abstract: Chemical compounds of formula (I): and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.Type: GrantFiled: October 16, 2003Date of Patent: December 5, 2006Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jon Mark Bentley, James Davidson, Matthew Alexander James Duncton, Richard Hugh Phillip Porter
-
Patent number: 6800627Abstract: Chemical compounds of formula (I): and pharmaceutically acceptable salts and addition compounds and prodrugs thereof are useful in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes inspidus, and sleep apnea.Type: GrantFiled: October 9, 2001Date of Patent: October 5, 2004Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jon Mark Bentley, James Davidson, Matthew Alexander James Duncton, Richard Hugh Phillip Porter
-
Publication number: 20040092525Abstract: Chemical compounds of formula (I): 1Type: ApplicationFiled: October 16, 2003Publication date: May 13, 2004Applicant: VERNALIS RESEARCH LIMITEDInventors: David Reginald Adams, Jon Mark Bentley, James Davidson, Matthew Alexander James Duncton, Richard Hugh Phillip Porter
-
Patent number: 6433175Abstract: A chemical compound of formula (I), wherein n is 1, 2 or 3; R1 and R2 are independently selected from hydrogen and alkyl; R3 is alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, or R5 and R6 together form a carbocyclic or heterocyclic ring, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders, diabetes insipidus, and sleep apnea, and particularly for the treatment of obesityType: GrantFiled: February 28, 2001Date of Patent: August 13, 2002Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jonathan Mark Bentley, Jonathan Richard Anthony Roffey, Richard John Hamlyn, Suneel Gaur, Matthew Alexander James Duncton, James Edward Paul Davidson, Michael John Bickerdike, Ian Anthony Cliffe, Howard Langham Mansell
-
Patent number: 6380238Abstract: For use in therapy a chemical compound of formula (I), wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, heterocyclyl, alkoxy, aryloxy, alkylthio, arylthio, alkylsulfoxyl, alkylsulfonyl, arylsulfoxyl, arylsulfonyl, amino, monoalkylamino, dialkylamino, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino, wherein at least one of R4 to R7 is a substituent group other than hydrogen, and pharmaceutically acceptable salts and prodrugs thereof, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and especially for the treatment of obesitType: GrantFiled: March 1, 2001Date of Patent: April 30, 2002Assignee: Vernalis Research LimitedInventors: David Reginald Adams, Jonathan Mark Bentley, Jonathan Richard Anthony Roffey, Richard John Hamlyn, Suneel Gaur, Matthew Alexander James Duncton, David Bebbington, Nathaniel Julius Monck, Claire Elizabeth Dawson, Robert Mark Pratt, Ashley Roger George